Knight Therapeutics Inc T.GUD

Impacted by end of agrements in LATAM- is this only Gilead ?

[Snowballgrowth]

Consolidated, no significant growth

[MrMugsy]

From what I recall - only Gilead. Also - there will always be quarters where growth stalls/pauses. What is the next leg of growth?  Likely further growth in Exelon to continue. Singular Genomics is likely at the end of its negative run on our numbers. I honestly haven't looked at the numbers closely yet - will eventually. Looks like Endo (Paladin) is taking a 20% haircut on thier sales

[gudisgood]

There were a few factors offsetting growth this quarter: No covid sales and no Gilead sales ($10.5M) Lower levels of Exelon sales due to advande buying in the last quarter ($2M) Lower levels of branded generics sales due to new competition Out of these, I would consider the branded generics a negative... but it's difficult to say how significant it is. I wish someone would have

[longrun86]

I think we can agree that it wasn't exactly the result we had hoped for. I am still optimistic for the platform in the long term. The GBT acquisition is still being worked out and the return profile has a ways to go yet before it reaches an acceptable level of return. My take is that Management has forgone short term returns to focus on building a stronger foundation for the business. The

[gudisgood]

I would agree that faith in management's ability is required in this case. I think we're always hoping for better quarters, but I truly don't think this was a bad quarter at all (not that you called it bad, but anyway). There's good/great growth in key products excluding Exelon and hopefully Exelon growth starts taking place now. The decline in branded generics is the negative

[curiousj]

keep in mind that Exelon is a branded generic and the focus with the new head of branded generics at Knight will be to right size the business and refocus on the right categories and brands... also branded generics from Argentina may not be sold across Latam, so figuring out the long-term plan still remains, and similarly the plan for exelon   

[Chianchin]

I totally agree the plan is to keep losing fortunes on generics, latam and argentina with inflation rate "oficlaly" 85% reality 200%.  Time to turf MNT and BDO out. Meir knew better  shame on those who fought him

[MrMugsy]

Absolutely - this is exactly how Samira/Goodman build a powerhouse in ROW. Selling in LATAM will always be evaluated and new strategies set if need be. Where to take Exelon will be discussed - rights in 15 or 16 countries (if I recall correctly). Where to manufacture will also come up - could Chile be added as a future manufacturing base? Might make an acquisition in Chile (or similar) more likely

[Chianchin]

This post has been removed in accordance with Community Policy

[russter]

Good for you CC, making it a mission keeping Mugsy in line. I get a good laugh from both of you guys? Alas you are right though GUD is probably the most boring sock on the TSX. And the USLESS managment are the only ones owning it because it constantly gives them a great paycheck, job security and lots of free travel. I agree with you managment needs to have their buts kicked out the door! But

[MrMugsy]

Agreed - always said it was a boring company and it will be ... until it isn't anymore. Also said it will move sideways until it doesn't anymore ... took 12 years to start moving as PLB ... guessing it will take about 10 years before it starts moving this time (maybe sooner but don't bet on it). Finally - no one is kicking management anywhere - they are in full control and will be

[Chianchin]

Boring beyond death. now in ER

[Chianchin]

The Kinight horse has only one leg left and few i..diots following 

[curiousj]

$6mn of OCF is due to settlement with GBT , equivalent to 50% of OCF for q3

[gudisgood]

Good point! :)

[Snowballgrowth]

Thank you for your response. A very good one !